Vertex Pharmaceuticals IncNASDAQ:VRTX
- LAST PRICE463.1500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots457.0000/ 3
- Ask / Lots467.0000/ 1
- Open / Previous Close--- / 463.1500
- Day Range---
- 52 Week Range
- Volume22
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRTX |
|---|---|---|
| 09:32 ET | 16618 | 460.235 |
| 09:34 ET | 1607 | 460.585 |
| 09:36 ET | 2050 | 458.1 |
| 09:38 ET | 2027 | 458.7701 |
| 09:41 ET | 2029 | 459.6947 |
| 09:43 ET | 421 | 459.595 |
| 09:45 ET | 1300 | 459.5 |
| 09:48 ET | 1950 | 459.14 |
| 09:50 ET | 4877 | 460.515 |
| 09:52 ET | 8152 | 461.485 |
| 09:54 ET | 1955 | 461.345 |
| 09:56 ET | 743 | 461.06 |
| 09:57 ET | 998 | 461.4 |
| 09:59 ET | 1426 | 461.13 |
| 10:01 ET | 9264 | 461.575 |
| 10:03 ET | 750 | 461.19 |
| 10:06 ET | 569 | 460.99 |
| 10:08 ET | 100 | 460.76 |
| 10:10 ET | 206 | 460.685 |
| 10:12 ET | 4529 | 460.705 |
| 10:14 ET | 2036 | 460.97 |
| 10:15 ET | 1159 | 461.085 |
| 10:17 ET | 225 | 461.0701 |
| 10:19 ET | 350 | 461.322 |
| 10:21 ET | 1100 | 460.79 |
| 10:24 ET | 800 | 460.745 |
| 10:26 ET | 200 | 460.68 |
| 10:30 ET | 2150 | 461.095 |
| 10:32 ET | 2895 | 461.06 |
| 10:33 ET | 6233 | 461.42 |
| 10:35 ET | 700 | 461.66 |
| 10:37 ET | 4732 | 462.14 |
| 10:39 ET | 900 | 462.33 |
| 10:42 ET | 926 | 462.17 |
| 10:44 ET | 2098 | 461.32 |
| 10:46 ET | 2103 | 460.35 |
| 10:48 ET | 1457 | 460.395 |
| 10:50 ET | 4553 | 460.05 |
| 10:51 ET | 500 | 459.98 |
| 10:53 ET | 900 | 459.84 |
| 10:55 ET | 2215 | 460.23 |
| 10:57 ET | 2251 | 460.065 |
| 11:00 ET | 1300 | 460.04 |
| 11:02 ET | 2250 | 460.66 |
| 11:04 ET | 680 | 460.925 |
| 11:06 ET | 1100 | 460.73 |
| 11:08 ET | 125 | 460.7256 |
| 11:09 ET | 5611 | 461.555 |
| 11:13 ET | 1300 | 460.66 |
| 11:15 ET | 4110 | 460.62 |
| 11:18 ET | 1000 | 460.67 |
| 11:20 ET | 100 | 460.5169 |
| 11:22 ET | 200 | 460.55 |
| 11:24 ET | 4569 | 460.86 |
| 11:26 ET | 6459 | 461.95 |
| 11:27 ET | 1548 | 462.5 |
| 11:29 ET | 740 | 462.955 |
| 11:31 ET | 1023 | 463.43 |
| 11:33 ET | 222 | 463.335 |
| 11:36 ET | 400 | 463.345 |
| 11:38 ET | 9936 | 463.865 |
| 11:40 ET | 600 | 463.87 |
| 11:42 ET | 1058 | 463.9 |
| 11:44 ET | 1900 | 463.675 |
| 11:45 ET | 600 | 463.35 |
| 11:47 ET | 835 | 463.66 |
| 11:49 ET | 1200 | 463.96 |
| 11:51 ET | 600 | 464.0442 |
| 11:54 ET | 800 | 464.57 |
| 11:56 ET | 300 | 464.765 |
| 11:58 ET | 400 | 464.5201 |
| 12:00 ET | 3495 | 464.805 |
| 12:02 ET | 628 | 464.865 |
| 12:03 ET | 908 | 464.75 |
| 12:05 ET | 1338 | 464.6 |
| 12:07 ET | 741 | 464.44 |
| 12:09 ET | 1200 | 464.965 |
| 12:12 ET | 1321 | 464.835 |
| 12:16 ET | 450 | 464.91 |
| 12:18 ET | 2441 | 464.4 |
| 12:20 ET | 337 | 464.33 |
| 12:21 ET | 300 | 464.275 |
| 12:23 ET | 1163 | 463.7425 |
| 12:25 ET | 755 | 463.81 |
| 12:27 ET | 200 | 463.8 |
| 12:30 ET | 685 | 463.38 |
| 12:32 ET | 800 | 463.57 |
| 12:34 ET | 100 | 463.565 |
| 12:36 ET | 200 | 463.395 |
| 12:38 ET | 1217 | 463.45 |
| 12:39 ET | 100 | 463.406 |
| 12:41 ET | 200 | 463.2 |
| 12:43 ET | 100 | 463.325 |
| 12:45 ET | 300 | 463.26 |
| 12:52 ET | 508 | 462.34 |
| 12:54 ET | 827 | 462.01 |
| 12:56 ET | 600 | 462.17 |
| 12:57 ET | 1500 | 461.4 |
| 12:59 ET | 300 | 461.66 |
| 01:01 ET | 400 | 461.625 |
| 01:03 ET | 500 | 461.69 |
| 01:06 ET | 4010 | 461.47 |
| 01:10 ET | 100 | 461.66 |
| 01:12 ET | 100 | 461.44 |
| 01:15 ET | 100 | 461.01 |
| 01:17 ET | 854 | 461.18 |
| 01:19 ET | 119 | 461.22 |
| 01:21 ET | 2052 | 461.18 |
| 01:24 ET | 4113 | 462.23 |
| 01:26 ET | 3023 | 462.33 |
| 01:28 ET | 400 | 462.34 |
| 01:32 ET | 102 | 461.95 |
| 01:33 ET | 502 | 462.64 |
| 01:35 ET | 250 | 462.1023 |
| 01:37 ET | 1302 | 461.83 |
| 01:39 ET | 300 | 461.75 |
| 01:42 ET | 416 | 461.71 |
| 01:46 ET | 1163 | 461.885 |
| 01:50 ET | 242 | 461.67 |
| 01:51 ET | 309 | 462 |
| 01:53 ET | 200 | 462.09 |
| 01:57 ET | 321 | 462.45 |
| 02:04 ET | 196 | 462.475 |
| 02:06 ET | 200 | 462.71 |
| 02:08 ET | 100 | 462.88 |
| 02:09 ET | 100 | 462.81 |
| 02:11 ET | 200 | 462.58 |
| 02:13 ET | 300 | 463.2 |
| 02:18 ET | 400 | 463.165 |
| 02:20 ET | 200 | 463.3795 |
| 02:22 ET | 1499 | 462.99 |
| 02:24 ET | 200 | 462.735 |
| 02:26 ET | 1997 | 462.92 |
| 02:29 ET | 200 | 462.6 |
| 02:31 ET | 350 | 462.07 |
| 02:33 ET | 500 | 462.005 |
| 02:38 ET | 200 | 462.125 |
| 02:40 ET | 100 | 462.16 |
| 02:42 ET | 200 | 461.93 |
| 02:44 ET | 502 | 462.41 |
| 02:47 ET | 600 | 462.485 |
| 02:51 ET | 200 | 462.16 |
| 02:54 ET | 360 | 462.345 |
| 02:56 ET | 621 | 462.48 |
| 02:58 ET | 2544 | 462.22 |
| 03:00 ET | 100 | 462.14 |
| 03:02 ET | 100 | 462.08 |
| 03:07 ET | 1694 | 461.97 |
| 03:09 ET | 1310 | 462.29 |
| 03:12 ET | 1144 | 462.255 |
| 03:14 ET | 753 | 461.83 |
| 03:16 ET | 100 | 461.96 |
| 03:18 ET | 1002 | 461.75 |
| 03:20 ET | 400 | 461.85 |
| 03:21 ET | 967 | 462.29 |
| 03:23 ET | 796 | 462.19 |
| 03:25 ET | 600 | 462.44 |
| 03:27 ET | 425 | 462.64 |
| 03:30 ET | 314 | 462.62 |
| 03:32 ET | 753 | 462.585 |
| 03:34 ET | 3767 | 462.44 |
| 03:36 ET | 1811 | 462.48 |
| 03:38 ET | 3545 | 462.43 |
| 03:39 ET | 798 | 462.48 |
| 03:41 ET | 600 | 462.55 |
| 03:43 ET | 1219 | 462.62 |
| 03:45 ET | 1089 | 462.605 |
| 03:48 ET | 900 | 462.72 |
| 03:50 ET | 327 | 462.55 |
| 03:52 ET | 5041 | 463.055 |
| 03:54 ET | 3921 | 463.23 |
| 03:56 ET | 9026 | 463.23 |
| 03:57 ET | 4914 | 463.02 |
| 03:59 ET | 169090 | 463.15 |
Yesterday
Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis, from 9:00AM ET on Thursday Sep 26, 2024 by Dow Jones
9:00AM ET on Thursday Sep 26, 2024 by Dow JonesVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA(R) at the North American Cystic Fibrosis Conference, from 7:07AM ET on Thursday Sep 26, 2024 by Dow Jones
7:07AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 25, 2024
DJ Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment, from 4:22PM ET on Wednesday Sep 25, 2024 by Dow Jones
4:22PM ET on Wednesday Sep 25, 2024 by Dow JonesHealth Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(R) (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, from 3:50PM ET on Wednesday Sep 25, 2024 by Dow Jones
3:50PM ET on Wednesday Sep 25, 2024 by Dow Jones
Sep 19, 2024
DJ Vertex Pharmaceuticals Price Target Maintained With a $431.00/Share by RBC Capital, from 10:27AM ET on Thursday Sep 19, 2024 by Dow Jones
10:27AM ET on Thursday Sep 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vertex Pharmaceuticals Inc | 119.5B | -228.8x | +46.35% |
Regeneron Pharmaceuticals Inc | 114.6B | 27.5x | +10.93% |
Biogen Inc | 28.2B | 24.4x | -18.14% |
ICON PLC | 23.7B | 33.3x | +4.68% |
IQVIA Holdings Inc | 43.1B | 30.6x | +46.62% |
Moderna Inc | 24.6B | -4.2x | --- |
Company Information
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Contact Information
- Headquarters
- 50 Northern AvenueBOSTON, MA, United States 02210
- Phone
- 617-341-6393
- Fax
- ---
Executives
- Executive Chairman of the Board
- Jeffrey Leiden
- President, Chief Executive Officer, Director
- Reshma Kewalramani
- Chief Financial Officer, Executive Vice President
- Charles Wagner
- Chief Operating Officer, Executive Vice President
- Stuart Arbuckle
- Executive Vice President - Global Research, Chief Scientific Officer
- David Altshuler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $119.5B |
|---|---|
Revenue (TTM) | $10.3B |
Shares Outstanding | 258.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-2.02 |
Book Value | $68.22 |
P/E Ratio | -228.8x |
Price/Sales (TTM) | 11.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
